INTRODUCTION
Despite the widespread use of Bacillus Calmette-Guérin (BCG) vaccine and effective drug therapy, tuberculosis (TB) still remains a major global health threat. The incidence of TB has dramatically increased worldwide in the past few decades by the synergy of HIV pandemic, the increasingly drug-resistant TB, e.g. multidrug-resistant and even extensively drug-resistant isolates, and the large scale mobility of the world population (Andersen, 2007; Reece & Kaufmann, 2008) . The currently available TB vaccine, BCG, has some undesirable drawbacks. Among them are an inefficiency in preventing adult pulmonary TB, lack of safety in immunocompromised individuals, interference with tuberculin skin test screening and considerably variable efficacy (Hesseling et al., 2003 (Hesseling et al., , 2007 Andersen & Doherty, 2005; Gupta et al., 2007; WHO, 2007) . Consequently, the development of safer and more efficient vaccines, as an alternative or complement to BCG, is urgently needed to facilitate worldwide control or eradication of TB in the future (Kaufmann, 2007; Young & Dye, 2006) . unique features compared to conventional live or subunit vaccines. The potency of plasmid DNAs expressing a variety of immunogenic Mycobacterium tuberculosis (Mtb) antigens has been intensively evaluated. Unfortunately, their performance is generally not superior to BCG, especially in large animals. However, the recent licensure of a DNA vaccine in horses highlights the potential of DNA vaccine technology in the prevention of TB infection (Ulmer et al., 2006) . Besides, it is generally believed that novel TB vaccines will be tested in the context of the widely used BCG and perhaps different kinds of vaccines are needed for the eradication of TB (Sander & McShane, 2007; Mitsuyama & McMurray, 2007) . As a result, enhancement of TB DNA vaccine efficacy has become the active field of current research.
It is well documented that VP22, a tegument protein of some alphaherpes viruses, has a unique property of being involved in intercellular transport and can be applied to improve DNA vaccine efficacy, despite uncertainty over the mechanism of action (Elliott & O'Hare, 1997; Phelan et al., 1998; Oliveira et al., 2001; Hung et al., 2001 Hung et al., , 2002 Michel et al., 2002; Zavaglia, et al., 2003; Qiu, et al., 2004; Kim et al., 2004; Zheng et al., 2005 Zheng et al., , 2006 Lemken et al., 2007b) . For this reason, bovine herpesvirus 1 VP22 (BVP22)-encoding DNA was chosen in the current study to test whether a fusion DNA vaccine created by the linkage of BVP22-encoding DNA to Mtb Ag85B-encoding DNA would induce an enhanced immune response and protection in C57BL/C mice compared to DNA encoding Ag85B alone. Another reason for selecting BVP22 was that it is the most efficient intercellular spreading motif identified according to the data available so far (Harms et al., 2000) . Ag85B is a well-known and well-characterized protein of Mtb, and plasmid DNA encoding Ag85B has shown partial protection in mice as well as in guinea pigs (Teixeira et al., 2006; Ko et al., 2005; Kamath et al., 1999; Lozes et al., 1997; Ulmer et al., 1997) .
METHODS
Plasmid construction. The gene encoding Ag85B was amplified from Mtb H37Rv genomic DNA with a forward primer, 59-TTTGGATCCGGCATGTTCTCCCGGCCGGGGCTG-39, containing a BamHI site and an initiation codon, and a reverse primer, 59-GATGAATTCAGCCGGCGCCTAACG-39, containing an EcoRI site and a termination codon. The resulting PCR product was ligated to pMD18-T vector (TaKaRa Bio) and then sequenced. The BVP22 sequence without a stop codon was isolated from pMD-BVP22 (kindly provided by Professor Xiao, Huazhong Agricultural University) by digestion with BglII and BamHI. The target genes encoding Ag85B and BVP22 were subsequently cloned into the eukaryotic expression plasmid pcDNA3.1(+) (Invitrogen), and the new plasmids were named pcAg85B and pcBVP22, respectively. For construction of pcBVP22-Ag85B, the BVP22 sequence was inserted to pcAg85B at the BamHI site, which is on the upstream of Ag85B sequence. These recombinant plasmids were confirmed by sequence analysis. The pcDNA3.1(+) plasmid was used as the negative control. All plasmids for transfection and animal immunization were prepared and purified using the Wizard Plus maxiprep purification system (Promega).
Expression and purification of recombinant protein in E. coli.
Expression of recombinant Ag85B protein in E. coli BL21 (DE3) was performed using the prokaryotic expression plasmid pET-28a, which contains the same insert as in pcAg85B and a 66His tag at the Nterminus to facilitate purification through Ni 2+ -charged column chromatography (Qiagen). Fractions were examined on an SDS-12 % polyacrylamide gel and recombinant protein detected by Western blot analysis using antisera from active TB patients. The protein was further purified according to the manufacturer's instructions and used as an antigen for identifying specific ELISA antibodies.
Transfection and detection of antigen expression. To evaluate in vitro expression of Ag85B and the fusion protein BVP22-Ag85B, HeLa cells [China Center of Type Culture Collection (CCTCC)] were transfected with the constructed plasmid DNAs using Lipofectamine 2000 reagent (Invitrogen) as described previously (Ju et al., 2005) . Cells were harvested 48 h after transfection and transient expression was detected by Western blot, using anti-recombinant-Ag85B antiserum developed in mice. The specificity of the antiserum had been tested previously using ELISA.
Immunization of mice and challenge. A total of 90 female C57BL/ 6 mice were randomly assigned to 6 groups of 15 mice each and immunized with plasmid constructs. These mice were obtained from the Animal Center of Wuhan University at specified-pathogen free grade, body weight 16-18 g, aged 4-6 weeks at the beginning of the experiment, and housed in the Animal Facility of Wuhan University with autoclaved food and water ad libitum. Infection studies were performed in a biosafety level 3 facility. The mice were inoculated intramuscularly with 50 ml 0.5 % bupivacaine hydrochloride (Sigma) into the quadriceps muscle of each hind leg, 5 days before immunization, followed by immunization with 100 ml sterile PBS with or without 100 mg plasmid construct intramuscularly three times at 2-week intervals. Six weeks after the last immunization, five mice from each group were sacrificed to determine the immunogenicity of the vaccines and controls at the time of challenge. The remaining ten mice per group were challenged intravenously in a lateral tail vein with 0.1 ml (10 6 bacilli) suspension of Mtb H37Rv per animal. Five weeks after challenge, all mice were sacrificed for assessment of bacterial growth and histopathological analysis as described previously . Negative controls were mice immunized with 100 ml PBS, pcDNA3.1(+) or pBVP22; the positive controls were mice inoculated with a single dose of BCG subcutaneously (10 6 c.f.u. per animal) at the time of the first prime dose of candidate DNA vaccine.
Analysis of Ag85B-specific antibody responses by ELISA. To evaluate anti-Ag85B humoral responses, sera were collected from five immunized mice in each group 6 weeks after the last immunization, and levels of anti-Ag85B total IgG antibody in serum samples were determined by ELISA. Briefly, each well was coated with 100 ml purified recombinant 85B protein (8 mg ml 21 ) overnight at 4 uC and incubated with 100 ml serial twofold dilutions of serum for 60 min at 37 uC, before the addition of 100 ml HRP-conjugated goat antimurine IgG (1 : 2000) and substrate solution TMB. Each sample was tested in triplicate. The reaction was stopped by addition of 2 M sulfuric acid and the absorbance was measured at 490 nm using a microplate reader (Tecan). Antibody titres were calculated as the highest dilution that gave a positive reading. The cut-off value was set as twice the mean absorbency of sera from the negative control.
Spleen lymphocyte proliferation assay. Spleen lymphocyte proliferation response was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric method. Briefly, splenocytes were prepared from five mice of each group and lymphocytes were isolated by density-gradient centrifugation on Ficoll-Hypaque. , 100 mg streptomycin ml 21 and 2 mM L-glutamine at 37 uC and 5 % CO 2 with or without Mtb antigen stimulation. After 68 h incubation, 10 ml MTT (Sigma) was added to each well and plates were incubated for a further 4 h. At the end of the incubation, the supernatants in each well were gently removed after the plates were centrifuged at 1000 r.p.m. (374 g) in a Heraeus Biofuge Stratos for 8 min; 150 ml DMSO were then added into each well to solubilize the formazan precipitates for 10 min under oscillation. The cells containing RPMI 1640/FBS only were used as a negative control and the cells stimulated with concanavalin A (5 mg ml
21
; Sigma) were used as a positive control. The stimulation index was calculated as the ratio of A 570 of stimulated to that of unstimulated proliferation. The recombinant protein Ag85B was used as the antigen in this study at a final concentration of 8 mg ml 21 .
Gamma interferon (IFN-c) ELISPOT assay. IFN-c-producing cells were quantified using a cytokine-specific enzyme-linked immunospot assay (ELISPOT) kit (U-Cytech) according to the manufacturer's instructions. Briefly, 96-well nitrocellulose-backed plates were coated with 100 ml anti-mouse IFN-c mAb overnight at 4 uC, then the wells were washed with PBS (pH 7.4) and blocked for 2 h with 5 % BSA. Lymphocytes isolated from the mouse spleen following treatment were added to the wells (2610 5 per well) and cultured for 18 h in RPMI 1640 alone (negative control) or with 8 mg ml 21 recombinant Ag85B or 5 mg ml 21 concanavalin A (positive control) in triplicate. After five washes with PBS containing 0.05 % Tween 20, 100 ml biotinylated rabbit anti-IFN-c antibody solution [prepared according to the guidelines of the manufacturer (U-Cytech)] was added per well and incubation continued for 1 h at room temperature. Following washes with PBS containing 0.05 % Tween 20, 50 ml Q-labelled antibiotin antibody solution [prepared according to the guidelines of the manufacturer (U-Cytech)] was added and incubated for 1 h at room temperature. After rewashing, 30 ml freshly prepared activator I/II solution were added to each well and plates were incubated at room temperature in the dark. Spots representing individual cytokineproducing cells were visualized by developing with the substrate 3-amino-9-ethylcarbazole and then counted using an immunospot image analyser.
Statistical analysis. Data were expressed as the means±SEM. Oneway ANOVA or Student's t-tests were performed using SPSS 11.5 software for comparison of results between different groups. P values ,0.05 were considered statistically significant.
RESULTS AND DISCUSSION

Expression of Mtb Ag85B-encoding gene in HeLa cells
The expression of Ag85B and fusion protein BVP22-Ag85B was examined by Western blot of the cell lysates following transfection of HeLa cells with pcAg85B and pcBVPAg85B. The study confirmed that cells transfected with these plasmids expressed the corresponding proteins, based on the anticipated size for Ag85B (~30 kDa) and BVP22-Ag85B (~65 kDa) (data not shown). In contrast, no band was observed in HeLa cells transfected with vector pcDNA3.1 or pcBVP22. These results verified the expression of the recombinant BVP22-Ag85B and Ag85B proteins in mammalian cells.
Evaluation of IgG antibodies and spleen lymphocyte proliferation
Levels of IgG antibodies and the lymphocyte proliferation induced by different vaccine schedules are shown in Figs 1 and 2. Both pcAg85B and pcBVP22-Ag85B elicited significantly higher levels of anti-Ag85B IgG antibodies and lymphocyte proliferation activities in mice (P,0.05 for both pcAg85B and pcBVP22-Ag85B immunized mice compared with the respective negative controls). Furthermore, pcBVP22-Ag85B vaccination significantly increased the levels of IgG antibodies and lymphocyte proliferation in mice compared with pcAg85B immunization (P,0.05), and achieved a similar effect to BCG. No Ag85B-specific antibodies and proliferation response were detected in mice receiving PBS or control vector pcDNA3.1 or pcBVP22. These results demonstrated that immunization with DNA encoding BVP22-Ag85B fusion protein significantly enhanced anti-Ag85B specific IgG antibody levels and cell proliferation in mice.
IFN-c production in response to Ag85B
IFN-c production in response to recombinant Ag85B was measured in three mice of each group by ELISPOT before challenge. The ELISPOT assay revealed that mice vaccinated with pcAg85B, pcBVP22-Ag85B and BCG demonstrated higher levels of IFN-c-producing cells in the spleen than did the PBS and vector controls. The highest number of IFN-c-producing cells was detected in mice vaccinated with BCG, followed by pcBVP22-Ag85B and pcAg85B. In addition, the pcBVP22-Ag85B-vaccinated mice showed a Mice were immunized with PBS, pcDNA3.1, pcBVP22, pcAg85B, pcBVP22-Ag85B or BCG. Sera were collected from five mice in each group 6 weeks after the last immunization. The total IgG titre against Ag85B protein was determined by ELISA. *, P,0.05 compared to the negative control groups (PBS, pcDNA3.1, or pcBVP22); # , P,0.05 compared to the pcAg85B-immunized group.
prominent trend for elevated numbers of antigen specific IFN-c-producing cells in the spleen in comparison to pcAg85B, even though it is not statistically significant (Fig. 3) . In contrast, mice injected with pc3.1 or pcBVP22 did not show any increased IFN-c-producing cell proliferation compared to PBS-immunized mice (P.0.05). These data indicated that linkage of BVP22 to Ag85B enhanced the effect of the DNA vaccine on IFN-cproducing T cells.
c.f.u. determination
Finally, we investigated whether the BVP22-Ag85B DNA vaccine enhanced protective efficacy against intravenous Mtb H37Rv infection in the C57BL/6 mouse model, based on the determination of bacterial load by c.f.u. counts in the lung and spleen at 5 weeks post-challenge. As shown in Table 1 , immunization with either pcAg85B or pcBVP22-Ag85B led to a significant reduction of mycobacterial loads in the lung or spleen in comparison to the PBS group (P,0.05). More importantly, mice vaccinated with pcBVP22-Ag85B demonstrated a significant reduction of mycobacterial loads and dissemination compared to those vaccines with pcAg85B alone (P,0.05). The effect of pcBVP22-Ag85B was not significantly different from that of BCG inoculation. No c.f.u. reduction was observed in the lung or spleen of mice vaccinated with either parental vector pc3.1 or pcBVP22 compared to the PBS group. We have further analysed the relationship between the c.f.u. reduction and IFN-c-producing response by Pearson correlation analysis and found that they are closely positively correlated (r50.99, P,0.01; data not shown).
Along with the data presented in Fig. 3 , these studies suggested that pcBVP22-Ag85B vaccine is superior to pcAg85B in both immunogenicity and protection efficacy, probably through amplification of IFN-c-producing cells.
Pathological changes in the lungs
To assess the degree of lung lesions present following mycobacterial challenge in vaccinated mice, mouse lung tissue was fixed, sectioned and then stained with either Ziehl-Neelsen acid-fast reagent or haematoxylin and eosin (HE). As shown in Fig. 4(a) , the Ziehl-Neelsen staining showed that mice immunized with pcAg85B, pcBVP22-Ag85B and BCG were able to inhibit the growth of tubercle bacilli in the lung after the challenge. The lungs of mice from the PBS, pcDNA3.1 and pcBVP22 groups displayed a much higher density of acid-fast bacilli than those of mice vaccinated with pcAg85B, pcBVP22-Ag85B or BCG, consistent with the mycobacterial growth data presented above. In HE staining sections (Fig. 4b) , lung tissue granulomatous lesions and inflammation changes were dramatically suppressed in mice vaccinated with pcAg85B, pcBVP22-Ag85B or BCG in comparison to the mice vaccinated with PBS, pcDNA3.1 or pcBVP22, which showed a significant amount of consolidation, seroplastic infiltrates, necrosis and multiple coalescing granulomatous lesions in most of the lungs. The alveolar tissue from ) for 68 h. Following incubation with MTT for 4 h, the absorbance was determined in a microplate reader at 570 nm. Samples were assayed in triplicate. Data represent the mean±SEM. *, P,0.05 compared to the negative control groups (PBS, pcDNA3.1, pcBVP22); # , P,0.05 compared to the pcAg85B-immunized group. The ELISPOT assay was performed as described in Methods.
Numbers represent mean numbers of spot-forming cells per 2¾10 5 lymphocytes. *, P,0.05 compared to the respective negative control groups. White bars, no stimuli; grey bars, Ag85B.
BVP22-encoding gene improved TB DNA vaccine efficacy intramuscularly three times at 2-week intervals. Six weeks after the last DNA immunization, the mice were challenged with Mtb H37Rv intravenously. dNumber of bacteria isolated from the organ at 35 days after an intravenous challenge with 10 6 c.f.u. of Mtb H37Rv per mouse (n55). §The reduction in bacterial counts in the lungs of plasmid-vaccinated mice relative to the PBS-vaccinated mice; *P,0.05, compared to respective negative controls; # P,0.05, compared to pcAg85B-immunized group. BCG-vaccinated mice appeared to be intact, with very limited lung inflammation. In pcAg85B-and pcBVP22-Ag85B-vaccinated mice, limited granulomatous lesions and slight inflammation were observed, especially in pcBVP22-vaccinated mice. Taken together, these results suggest that pcAg85B, pcBVP22-Ag85B and BCG vaccination enhanced mouse immunity, improved protection against mycobacterial bacterial growth, and curtailed bacteria-induced inflammation.
Naked DNA vaccines have emerged as an attractive approach for novel TB vaccine development, and efforts have been made continuously to improve the immunogenicity of DNA vaccines by several strategies. VP22, a tegument protein of some alphaherpes viruses, has been reported to exhibit an unusual intercellular trafficking property of mediating protein spread from cell to cell, alone or as apart of fusion protein (Lemken et al., 2007a; Zheng et al., 2006; Mwangi et al., 2005; Michel et al., 2002; Elliott & O'Hare, 1997) . Recent studies have further demonstrated that DNA constructs that encode fusion proteins of VP22 linked to an antigen can increase the potency of DNA vaccines in inbred and outbred animals (Zheng et al., 2005; Saha, et al., 2006; Mwangi et al., 2007; Zakhartchouk et al., 2007) . However, the capacity of VP22 to improve the immunogenicity and efficacy of TB DNA vaccines containing mycobacterial antigens remains to be elucidated. In our study, Ag85B, one of the most important immunogenic antigens of Mtb, was fused to BVP22 to investigate whether this linkage of BVP22 and Ag85B can improve the potency of Ag85B DNA vaccine. Our data clearly showed that vaccination with naked DNA encoding BVP22-Ag85B fusion protein significantly enhanced the Ag85B-specific Th1-type immune responses in C57BL/6 mice, as demonstrated by a significant enhancement of lymphocyte proliferation and specific antibody level compared to Ag85B DNA immunization. The intercellular trafficking property of VP22 might contribute to the enhanced immune responses, similar to results from previous studies in which VP22 was demonstrated to enhance the immunogenicity of various antigens fused to VP22. However, other mechanisms may play a role in the action of VP22 in the current study. Some researchers have found that VP22 contains T-cell epitopes (Braun et al., 2006) . During immunization with the fusion protein, it is possible that the antigenic epitopes on VP22 stimulate lymphocytes and contribute to an inflammatory response that subsequently improves the antigen-specific response to antigen Ag85B. Clearly, the exact mechanism of action of VP22 remains to be elucidated. We believe that this can be achieved, at least partially, by evaluating the immune response in mice immunized with both pcBVP22 and pcAg85B plasmids, which is part of our future study.
Although mice immunized with pcBVP22-Ag85B did not show a significant difference in the numbers of IFN-cproducing cells in comparison with those immunized with pcAg85B alone, they clearly showed enhanced protection because the bacterial load both in the lung and spleen were significantly reduced and lung pathology was prominently improved. We believe that this is probably due to an amplified immune response as the results of linear correlation analysis revealed that log c.f.u. reduction in the lung was closely correlated with IFN-c response.
In summary, our data have demonstrated that incorporation of the BVP22-encoding gene into a DNA vaccine encoding Mtb Ag85B enhanced the Ag85B-specific immune response and protection efficacy against intravenous Mtb H37Rv challenge. Such an approach may be used to improve the potency of vaccines against TB in the future.
